Printed from Voxsanity (voxsanity.com.au) — NCT06738849 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Type 1 Diabetes
Type 1 Diabetes Trial, Recruiting
NCT06738849
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or over
- People who have type 1 diabetes, type 2 diabetes, or diabetes caused by a pancreatic disease
- People who have been using multiple daily insulin injections (a background insulin plus mealtime insulin) for at least 6 months
- People whose rapid-acting insulin is one of the following: Novorapid, Humalog, Apidra, Asparte Sanofi, Fiasp, or Lyumjev
- People whose long-acting (background) insulin is one of the following: Lantus, Abasaglar, Toujeo, Levemir, or Tresiba
- People who have been using a continuous glucose monitoring (CGM) device — such as Dexcom G6, Dexcom One, Dexcom One+, or FreeStyle Libre — for at least 3 months
- People who have already given their doctor access to their glucose data through a data management platform
- People with type 2 diabetes who take other blood sugar-lowering medications (besides insulin) and whose dose has not changed in at least 3 months
- People whose CGM device recorded glucose readings for at least 70% of the time over a 14-day period close to the time of joining
- People who have access to at least one smartphone (Android 5.0 or higher, or iOS 12.0 or higher) connected to the internet and able to receive CGM data
- People who can read and use a smartphone without needing special large-text settings
- People who could become pregnant must either have had a pregnancy test before joining, or be using an effective method of contraception
- People enrolled in the French social security system
Who may not be able to join:
- Women who are pregnant or breastfeeding
- People with type 1 diabetes who take blood sugar-lowering medications other than insulin (such as sulfonamide-based tablets or SGLT-2 inhibitors)
- People whose prescribed daily insulin dose is more than 1 unit per kilogram of body weight per day, or more than 200 units per day (considered insulin-resistant)
- People whose daily insulin dose is less than 15 units per day (very low insulin requirements)
- People who have a condition called gastroparesis (delayed stomach emptying)
- People who have had a serious episode of diabetic ketoacidosis, or a severe low blood sugar episode requiring help from another person, within the 6 months before joining
- People whose pancreatic disease is caused by long-term heavy alcohol use
- People with another known medical condition that the trial doctor believes could interfere with the study (confirm with trial site)
- People who cannot be followed up for the full 3-month study period
- People whose intellectual ability would make it difficult to use the app, understand instructions, or complete questionnaires
- People who have taken part in another clinical trial or received an unauthorised medication in the 4 weeks before screening
- People currently within an exclusion period from another research study
- People under legal guardianship or curatorship
- People who are imprisoned or otherwise not free to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Phone: +33 6 27 17 79 49
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
DiappyMed
Registry
ClinicalTrials.gov
Start date
5 November 2024
Est. completion
30 May 2026
Where this trial is recruiting
🇫🇷 France
Primary endpoints
Change in the percentage of time in range 70-180 mg/dL
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.